Physician profile

John Mark

Sacramento, CA

NPI 1720692775

$3,102.81

in general payments reported to CMS, 2019-2025

3 companies · $2,847 in 2025

The $2,847 reported for 2025 was more than what 96% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$2,250.00
Food and Beverage$852.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Regeneron Pharmaceuticals, INC. $2,500.00 2025
Alcon Vision LLC $427.09 2023-2025 Hydrus Microstent, Clareon, Centurion
Sight Sciences, INC. $175.72 2025 Omni Surgical System, Sion Surgical Instrument

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Mark

$3,102.81

in general payments reported 2019-2025

Years
2023-2025
Top company
Regeneron Pharmaceuticals, INC.
Context
The $2,847 reported for 2025 was more than what 96% of providers received nationally.

https://glasscript.com/doctor/11553463/john-mark

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.